findmyKOL

Timothy Moore, MD

Basic profile

Medical Oncology

ORCIDNone on fileNPI
RegionColumbus, OH · MidwestSpecialtyMedical OncologyFocusOncology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationNot yet indexedOnline presenceNot yet checkedPayments2021 onwardNIH funding2016–2022Why? →

Timothy Moore is an Oncology physician.

Overview

Scholarship

indexed output and impact (OpenAlex)

Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →

Clinical & industry

trials, payments and federal funding
47companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments
1NIH grants · 2016–2022

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

3100 Plaza Properties Blvd
Columbus, OH 432191530

Telephone

614-383-6000

Provider last certified this registry record 11 Jan 2023.

View the NPPES registry record

Industry payments

47 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    43.4%
    Kinase inhibitor13.3%
    Brukinsa37%Imatinib Mesylate20%Imbruvica20%Jakafi11%Tasigna11%
    Part D<11 patients
    Thalidomide Analog9.1%
    Revlimid100%
    Part D13 patients

    + 6 more classes in this area

  • Nervous system

    24.1%
    Opioid Agonist15.1%
    Oxycodone Hcl49%Oxycodone-Acetaminophen28%Fentanyl23%
    Part D<11 patients
    Phenothiazine5.3%
    Prochlorperazine Maleate100%
    Part D24 patients

    + 2 more classes in this area

  • Metabolism & gastrointestinal

    15.7%
    Corticosteroid10.6%
    Prednisone100%
    Part D26 patients
    Serotonin-3 Receptor Antagonist3.5%
    Ondansetron Odt100%
    Part D12 patients

    + 1 more class in this area

Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

1 NIH research award on record, funded 20162022 per NIH RePORTER. The latest:

4 more award records behind the reveal.Reveal →

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”